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Abstract. Investigation of the nucleotide sequence of the 
HIV-1 LTR showed the presence of four novel short DNA 
regions which are homologous to the recognition site for the 
cellular transcription factor AP-1. Four short oligonucleotide 
hybrids containing these potential AP-1 sites were 
constructed and used in gel retardation assays and in 
competition experiments in order to determine the role of the 
AP-1 protein in the regulation of HIV-1 expression. The 
breast MDA MB 468 and cervical HeLa tumor cell lines, 
which are known to overexpress the AP-1 protein were used 
in a gel retardation assay as a control to study the affinity of 
the AP-1 to synthesized oligonucleotide sequences. We have 
observed specific binding of nuclear factor AP-1 to three of 
these oligonucleotide hybrids. These results demonstrate the 
presence of three novel AP-1 binding sites on HIV-1 LTR, 
one of which was found within the TAR element and in the 
Tat protein binding region. Moreover, they suggest that AP-1 
could be contributing to HIV-1 transcriptional regulation 
through its interaction with the AP-1 binding sites of HIV-1 
LTR. 
Introduction 
The human immunodeficiency virus type 1 (HIV-1) is the 
etiologic agent and the primary cause of AIDS (1-3). The 
expression of the virus is regulated both at transcriptional and 
post-transcriptional levels by several human and viral 
proteins (4-6). Control of HIV-1 transcription is mediated by 
c/s-acting elements located in the viral long terminal repeats 
(LTRs), by the viral trans-regulatory protein Tat, and by 
cellular transcription factors which are constitutively 
expressed in most cells (e.g. NF-κΒ and NFAT-1) (7). eis 
elements include the negative regulatory element (NRE, 
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located in the region between nucleotide positions -357 to -185 
relative to the transcription initiation site +1), the enhancer 
(-103 to -81), the Spi element (-75 to -47), and the TATA 
box (-28 to -24). The irans-regulatory element TAR is 
located between residues -17 to +80. Various cellular 
proteins have been found to interact with the eis elements, 
such as AP-1 (8) and USF (9) with NRE; EBP-1 with the 
enhancer (10); Spi with the sequence motif Spi (11) and 
TFIID with the TATA box (12). The viral protein Tat 
interacts with the frans-regulatory element TAR (5,13,14). 
The AP-1 binding site was initially described in the enhancer 
elements of the Simian Virus 40 promoter and the human 
metallothionein IIA promoter (15). A group of polypeptides 
originally purified from HeLa cells was designated as 
transcription factor AP-1 on the basis of DNA binding 
specificity and in vitro transcriptional analysis (16). The 
proteins named AP-1 in fact represent a family of 
transcription factors encoded by the members of the jun and 
fos multigene families able to bind as homo- and/or 
heterodimers to the AP-1 consensus (17,18). 
Two binding sites for transcription factor AP-1 have been 
mapped within the NRE of HIV-1 LTR. Sequences between 
nucleotides -348 to -343 and -336 to -331 are similar to HeLa 
cell AP-1 binding sites and have been shown to interact with 
the FOS-complex and FOS-related antigens (8). In this study 
we have further examined the HIV-1 LTR, and we have 
identified three additional AP-1 binding sites one of which 
was found within the TAR element. According to this result, 
AP-1 could be contributing to the HIV-1 transcriptional 
regulation through its interaction with AP-1 binding sites of 
HIV-1 LTR. 
Materials and methods 
Cells and culture conditions. Human MDA MB 468 breast 
and HeLa cervical epithelial tumor cells were grown 
exponentially in Ham's medium containing 10% fetal calf 
serum and used for the preparation of nuclear extracts. 
Preparation of cell extracts. The tumor cell lines were 
homogenized in 2 ml hypotonic buffer (25 mM Tris-HCl pH 
7.5 KCl, 0.5 mM MgCl2, 0.5 mM DTT, 0.5 mM PMSF) at 5-
10 mg/ml. The nuclei were pelleted at 2500 rpm in a Sorvall 
SS34 rotor for 10 min at 4°C. The pellets were washed 3 
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times with 2 ml isotonic buffer (25 mM Tris-Cl pH 7.5, 5 
mM KCl, 0.5 mM MgCl2, 0.1 M sucrose, 0.5 mM DTT, 1 
mM PMSF), resuspended in nuclei extraction buffer (25 mM 
Tris-Cl pH 7.5, 1 mM EDTA, 0.1% NP40, 0.5 mM DTT, 0.5 
mM PMSF) and were further clarified after centrifugation at 
25000 rpm in a Beckman Ti 50 rotor for 60 min at 4°C. 
Supernatant was removed and the extracts were stored at -70°C. 
Protein estimation was performed as described by Bradford 
(19). 
Preparation of double stranded oligonucleotide hybrids. 
Eight single stranded DNA oligonucleotides were made on 
an Applied Biosystems 381A DNA synthesizer. These were: 
1 a AGCTT A AG ACC A ATGACTT AC AAGGC AGC A 
1 b ATTCTGGTTACTGAATGTTCCGTCGTTCGA 
2a AGCTTCTAGTACCAGTTGAGCCAGAGAAGTTA 
2b AGATCATGGTCAACTCGGTCTCTTCAATTCGA 
3a AGCTTCATGGAATGGATGACCCGGAGAGAGAA 
3b AGTACCTTACCTACTGGGCCTCTCTCTTTCGA 
4a AGCTTAGACCAGATCTGAGCCTGGGAGCTCTCTTA 
4b ATCTGGTCTAGACTCGGACCCTCGAGAGAATTCGA 
The oligonucleotides were removed from the synthesis 
column by elution with 3x1 ml of ammonia. This solution 
was incubated at 55°C overnight to deprotect the 
oligonucleotides. To further purify the oligonucleotides, an 
Applied Biosystems oligonucleotide purification cartridge 
(OPC) was used. To anneal complementary single stranded 
oligonucleotides (i.e. la to lb) they were both incubated at a 
concentration of 0.05 M in TE. The solution was then heated 
to 90°C and allowed to cool slowly to less than 30°C. This 
results in the formation of double stranded oligonucleotide 
hybrids. To check the succession of the annealing the double 
stranded oligonucleotide hybrids were run on an 8% 
Polyacrylamide gel alongside the single-stranded oligo­
nucleotides. 
Double stranded oligonucleotides were 5' end-labelled 
using γ32Ρ-ΑΤΡ and T4 polynucleotide kinase and end filled 
using the Klenow fragment of DNA polymerase according to 
Maniatis et al (20). 
Oligonucleotide labelling. The above described oligo­
nucleotide hybrids and the oligonucleotide E3AP-1 
representing the region between nucleotides -81 and -103 at 
the ElA-inducible E3 promoter (21) were labelled with γ32Ρ-
ATP using T4 polynucleotide kinase from Boehringer. The 
oligos were incubated sequentially at 37°C for 30 min, at 
70°C for 5 min, at 37° for 10 min, at RT for 5 min and on ice 
for 5 min. 
Gel retardation assays. DNA binding reactions were carried 
out as follows: 2000 cpm Y32P-oligo were mixed with nuclear 
proteins (20 μg) in binding buffer (50 mM Hepes pH 8.0, 
500 mM NaCl, 0.5 mM PMSF, 0.5 mg/ml BSA, 20% 
glycerol, 1 mM EDTA) plus 1 mM DTT and 150 μg/ml 
poly(dl-dC). The reaction mixture was left for 30 min at 0°C. 
Samples were subjected to electrophoresis on 5% 
Polyacrylamide gels, dried and exposed to X-ray film (RX 
Fuji, Japan). 
A rabbit polyclonal antibody to the human JUN protein 
(a gift from Dr D. Gillespie, The Beatson Institute, Glasgow, 
UK) was employed in gel mobility shift assays. 
Results 
The HIV-1 LTR contains four short DNA regions (lab to 
4ab) which are homologous to the recognition site for the 
cellular transcription factor AP-1 (Fig. 1). From these four 
sequences, the AP-1 like sequence in the region 2ab shows 
the highest homology (85.8%) to the AP-1 consensus and 
therefore the corresponding oligonucleotide hybrid 2ab was 
initially used to test the affinity of the AP-1 protein in MDA 
MB 468 and HeLa tumor cell lines. This was achieved by 
preparing nuclear extracts, mixing them with y32P-end 
labelled double stranded oligonucleotides E3AP-1 and 2ab 
and analysing the formation of DNA-protein complexes by 
gel retardation assays. In addition, we also examined whether 
the remaining non-tested AP-1-like sites on HIV-1 LTR are 
functional. In Fig. 2 is shown a panel of lanes with 
competition experiments between 2ab end-labelled 
oligonucleotide and the representative set of AP-1-like sites 
in HIV-1 LTR (lab or 2ab or 3ab or 4ab) oligonucleotides. 
These competition reactions were performed on the MDA 
MB 468 tumor cell line. The lab, 2ab and 4ab 
oligonucleotides compete to a different extent depending on 
their homology to AP-1 consensus (see Fig. 1) for the 
labelled 2ab oligonucleotide. This is not surprising since lab 
and 4ab are highly homologous (71.5% to the E3AP-1 which 
contains the AP-1 binding consensus from the E3 promoter) 
(21), (Fig. 1). However, the non-labelled oligonucleotide 
hybrid 3ab did not compete for AP-1 binding activity with 
the labelled oligonucleotide hybrid 2ab, presumably because 
it shares only a limited homology (57.1%) to the AP-1 
consensus. 
To test further whether these putative AP-1 binding sites 
are functional, the control end-labelled oligonucleotide 
hybrid E3AP-1 was used in competition reactions with lab, 
2ab 3ab, 4ab or non-labelled E3AP1 oligonucleotide in 
nuclear extracts from the MDA MB 468 tumor cell line. As 
shown in Fig. 3 non-labelled oligonucleotides E3AP-1, 2ab 
and 4ab compete well, lab compete weakly and 3ab does not 
compete to the labelled oligonucleotide E3AP-1 for DNΑ­
ΑΡ- 1 protein complex formation. The oligonucleotide hybrid 
2ab was then used to test the presence of AP-1 activity in 
HeLa cells. Competition experiments (Fig. 4, lanes 3 to 5) 
showed that in all cases non-labelled lab, 2ab and 4ab 
oligonucleotides compete for end-labelled 2ab oligo­
nucleotide. 
We have shown the effect of JUN antibody on the 
formation of the DNA-protein complex between E3AP-1 and 
the AP-1 protein from HeLa nuclear extracts. In Fig. 5 is 
shown the effect of JUN antibody on the formation of the 
DNA-protein complex between E3AP-1 and the AP-1 protein 
in HeLa nuclear extracts (lane 6). Also in the same Figure is 
shown that the non-labelled oligonucleotide hybrids lab or, 
2ab and 4ab competed with the labelled oligonucleotide 
hybrid E3AP-1 for DNA-AP-1 protein complex formation 
(lanes 3-5), therefore suggesting that these binding sites are 
likely to be functional. 
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Figure 1. Schematic representation of the HIV-1 LTR. The locations of NRE, enhancer and TAR sequences are shown. The nucleotide sequence of AP-1 
consensus is shown as well as the nucleotide sequences of putative AP-1 sites located in the HIV-1 LTR alongside their nucleotide position. Nucleotide 
differences between AP-1 consensus and HIV-1 LTR AP-1 sequences are underlined. 
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Figure 2. Effect of competitor sequences on gel electrophoretic mobility 
shift. Nuclear extracts from MDA MB 468 cells were incubated with γ32Ρ-
end labelled E3AP-1 and 2ab-AP-l oligonucleotide hybrid (lanes 1 and 2-6, 
respectively). In competition assays, 200-fold excess of cold competitor 
oligonucleotides 1 ab, 2ab, 4ab and 3ab (lanes 3-6), were incubated with the 
same nuclear extracts. The DNA-AP-1 protein complex is indicated by the 
arrow. 
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Figure 3. Effect of competitor sequences on gel electrophoretic mobility 
shift. Nuclear extracts from MDA MB 468 tumor cells were incubated with 
Y32P-end labelled E3AP-1 oligonucleotide hybrid. In competition assays, 
200-fold excess of cold competitor oligonucleotides E3AP-I and lab, 2ab, 
4ab and 3ab (lanes 2 and 3-6, respectively), were incubated with the nuclear 
extracts before adding the probe. The DNA-AP-1 protein complex is 
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Figure 4. Effect of competitor sequences on gel electrophoretic mobility 
shift. Nuclear extracts from HeLa cells, were incubated with y32P-end 
labelled Ε,ΑΡ-1 and 2ab-AP-l oligonucleotide hybrids (lanes 1 and 2-5, 
respectively). In competition assays, 200-fold excess of cold competitor 
oligonucleotides lab, 2ab and 4ab (lanes 3-5), were incubated with the 
nuclear extracts before adding the probe. The DN AAP-1 protein complex is 
indicated by the arrow. 
Discussion 
CELLS : 
Γ 
ANTIBODY : 
Γ 
COMPETITOR : 
PROBE: [ 
a. < 
_ m 
HeLa 
a a η 
CO CS 03 y- c\i *3-
63AP' 
,1 
1 
1 
AP-1 -
FREE 
DNA 
LANE 
Figure 5. Effect of competitor sequences and JUN antibody on the AP-1/ 
oligonucleotide complexes analyzed by gel electrophoretic mobility shift. 
Nuclear extracts from HeLa cells incubated with γ32Ρ-εηα labelled E3AP-1 
oligonucleotide hybrid. In competition assays, 200-fold excess of cold 
competitor oligonucleotides lab, 2ab, 4ab and E,AP-1 (lanes 2-4 and 5, 
respectively), were incubated with the nuclear extracts before adding the 
probe. IUN antibody and nuclear extracts from HeLa cells were incubated 
with Ε,ΑΡ-1 oligonucleotide (lane 6). The shift in the mobility of the JUN 
complex is indicated by the arrow. 
In this study we found that the HIV-1 LTR contains three 
novel AP-1 binding sites. One of the three novel AP-1 sites 
was found, within the TAR region, one within NRE and the 
other further upstream. All three sites are functional since 
their corresponding oligonucleotide hybrids compete one 
another as well as the oligonucleotide hybrid E3AP-1 which 
contains the AP-1 binding site of the E3 inducible promoter. 
The potential transcriptional regulation of HIV-1 gene 
expression by the AP-1 binding site within NRE is further 
supported by the fact that Curran and his colleagues have 
identified two additional AP-1 sites in this LTR region (8). 
However, the novel AP-1 site we found within the TAR 
region appears to be of even greater interest. Maximal 
expression of proviral HIV-1 DNA is attributed mainly to the 
Tat protein, which is thought to function at the transcriptional 
level through a nascent RNA copy of the TAR region. 
According to Berkhout and his colleagues the Tat protein 
could target the LTR transcriptional unit directly bypassing 
the use of TAR RNA (22). In this instance it is possible that 
AP-1 protein could participate in this mechanism through 
TAR DNA sequence. Further experiments are needed to test 
this hypothesis. 
Although our study demonstrated novel AP-1 binding 
sites in the HIV-1 LTR sequences, further studies would be 
required to establish a functional relationship of these HIV 
LTR AP-1 binding sites and the elevated AP-1 levels in the 
HIV life cycle. 
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